Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1217117.RAM0_i9P0Z8fdVtm0xAq4URpkVe7qdF0fCyKI3R9m43jE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1217117.RAM0_i9P0Z8fdVtm0xAq4URpkVe7qdF0fCyKI3R9m43jE130_assertion type Assertion NP1217117.RAM0_i9P0Z8fdVtm0xAq4URpkVe7qdF0fCyKI3R9m43jE130_head.
- NP1217117.RAM0_i9P0Z8fdVtm0xAq4URpkVe7qdF0fCyKI3R9m43jE130_assertion description "[The performance of miRNAs 21 and 221 in differentiating prostate cancer from nonmalignant cases was evaluated and compared to DRE and elevated PSA. miRNA 21 was overexpressed in 90�% of group A vs. 10�% of group B, while miRNA 221 was overexpressed in 80�% of group A vs. 20�% of group B (p?=?0.001).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1217117.RAM0_i9P0Z8fdVtm0xAq4URpkVe7qdF0fCyKI3R9m43jE130_provenance.
- NP1217117.RAM0_i9P0Z8fdVtm0xAq4URpkVe7qdF0fCyKI3R9m43jE130_assertion evidence source_evidence_literature NP1217117.RAM0_i9P0Z8fdVtm0xAq4URpkVe7qdF0fCyKI3R9m43jE130_provenance.
- NP1217117.RAM0_i9P0Z8fdVtm0xAq4URpkVe7qdF0fCyKI3R9m43jE130_assertion SIO_000772 25190021 NP1217117.RAM0_i9P0Z8fdVtm0xAq4URpkVe7qdF0fCyKI3R9m43jE130_provenance.
- NP1217117.RAM0_i9P0Z8fdVtm0xAq4URpkVe7qdF0fCyKI3R9m43jE130_assertion wasDerivedFrom befree-2016 NP1217117.RAM0_i9P0Z8fdVtm0xAq4URpkVe7qdF0fCyKI3R9m43jE130_provenance.
- NP1217117.RAM0_i9P0Z8fdVtm0xAq4URpkVe7qdF0fCyKI3R9m43jE130_assertion wasGeneratedBy ECO_0000203 NP1217117.RAM0_i9P0Z8fdVtm0xAq4URpkVe7qdF0fCyKI3R9m43jE130_provenance.